Salipro Biotech and Bio-Rad Laboratories Inc. Present Novel CXCR4-Targeting Antibodies at PEGS Boston

We're excited to announce the first results from our collaboration with Bio-Rad, leveraging our Salipro® platform with Bio-Rad’s Pioneer™ Antibody Discovery Platform.

This combination has yielded multiple novel human antibodies targeting wildtype CXCR4 with affinities similar to or exceeding ulocuplumab! These new CXCR4-targeting antibodies inhibit CXCL12 mediated cell migration similar or even better than ulocuplumab and offer the potential for enhanced efficacy and novel therapeutic avenues. 

Join us at PEGS Boston to learn more about these exciting findings! We'll be delving deeper into the data at our Poster A080 and the presentation by Francisco Ylera (Bio-Rad) on Monday 13th at 2:45pm during the Display of Biologics session.